The SELECT Trial: How GLP-1 Medications Reduce Heart Disease Risk

Understanding the SELECT Trial and GLP-1 Heart Health Research

The SELECT trial stands as one of the most important clinical studies ever conducted on GLP-1 medications. Published in 2023, this groundbreaking research demonstrated that semaglutide—the active ingredient in medications like Wegovy and Ozempic—does far more than help people lose weight. It can actually reduce the risk of heart attacks, strokes, and cardiovascular death.

For years, doctors prescribed GLP-1 medications primarily for type 2 diabetes and weight management. The SELECT trial changed that conversation entirely, revealing powerful cardiovascular benefits that extend well beyond blood sugar control and the scale.

If you're considering GLP-1 therapy or currently taking semaglutide or tirzepatide, understanding this research helps you appreciate the full scope of these medications' potential health benefits.

What Does SELECT Stand For?

SELECT stands for Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity. The trial was specifically designed to answer one crucial question: Can semaglutide reduce cardiovascular events in people with existing heart disease who are overweight or obese, but don't have diabetes?

This distinction matters. Previous studies had shown cardiovascular benefits in people with type 2 diabetes. SELECT wanted to know if those same protective effects existed for people without diabetes—a much larger population at risk for heart disease.

The trial enrolled over 17,600 participants across 41 countries, making it one of the largest cardiovascular outcome trials ever conducted for a weight management medication.

Key Findings from the SELECT Trial

The results surprised even the researchers. Participants taking semaglutide experienced a 20% reduction in major adverse cardiovascular events compared to those taking a placebo. This category includes heart attacks, strokes, and cardiovascular death—the most serious outcomes cardiologists work to prevent.

Breaking down the specific results:

• Cardiovascular death, heart attack, or stroke occurred in 6.5% of the semaglutide group versus 8% in the placebo group
• The benefit appeared early and sustained throughout the trial period
• Participants lost an average of 9.4% of their body weight on semaglutide versus 0.9% on placebo
• The cardiovascular benefits appeared independent of the amount of weight lost

That last point is particularly important. While weight loss certainly contributes to better heart health, the SELECT trial suggested semaglutide offers cardiovascular protection beyond what weight loss alone would explain.

How GLP-1 Medications Protect Heart Health

Researchers believe GLP-1 medications like semaglutide protect the cardiovascular system through multiple mechanisms:

Reduced inflammation: GLP-1 receptors exist throughout the cardiovascular system. Activating these receptors appears to reduce systemic inflammation, a key driver of atherosclerosis and heart disease.

Improved blood pressure: SELECT participants experienced modest but meaningful reductions in blood pressure, decreasing strain on the heart and blood vessels.

Better lipid profiles: GLP-1 medications can improve cholesterol levels, though this wasn't the primary driver of SELECT's results.

Direct vascular effects: Animal studies suggest GLP-1 may directly protect blood vessel walls and improve endothelial function—how well blood vessels dilate and contract.

The exact combination of these mechanisms continues to be studied. What's clear is that GLP-1 medications offer cardiovascular benefits that work through multiple pathways simultaneously.

What SELECT Means for Patients and Healthcare

The SELECT trial fundamentally changed how cardiologists and primary care doctors view GLP-1 medications. These are no longer just diabetes or weight loss drugs—they're legitimate cardiovascular medications with proven protective effects.

For patients with existing heart disease who are overweight or obese, semaglutide represents a new option for reducing future cardiovascular events. The American Heart Association and other major cardiology organizations have already begun incorporating SELECT's findings into clinical guidelines.

Insurance coverage is also evolving. Some insurers now cover GLP-1 medications for cardiovascular risk reduction, though coverage varies widely. This represents a significant shift from viewing these medications as primarily cosmetic weight loss tools.

You can read more about GLP-1 medications and their various health benefits on our blog at ozarihealth.com/blog.

Limitations and Ongoing Research

While SELECT's results are impressive, some important limitations exist. The trial only studied people who already had cardiovascular disease. Whether semaglutide prevents first heart attacks in people without existing heart disease remains unknown, though other trials are investigating this question.

The study used a specific dose of semaglutide (2.4 mg weekly). How other doses or other GLP-1 medications like tirzepatide compare requires additional research, though early evidence suggests similar cardiovascular benefits across the class.

Researchers are also still working to understand exactly why GLP-1 medications protect the heart. The more we understand these mechanisms, the better we can optimize treatment strategies.

Key Takeaways

• The SELECT trial demonstrated that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with existing heart disease
• These cardiovascular benefits appear to work through multiple mechanisms beyond just weight loss, including reduced inflammation and improved blood vessel function
• SELECT has transformed how doctors view GLP-1 medications, establishing them as legitimate cardiovascular protective therapies, not just weight loss drugs
• Ongoing research continues to explore cardiovascular benefits in broader populations and with other GLP-1 medications like tirzepatide

Frequently Asked Questions

Does tirzepatide have the same cardiovascular benefits as semaglutide?

While tirzepatide hasn't yet completed a cardiovascular outcomes trial as large as SELECT, early evidence is promising. The SURMOUNT trials showed similar metabolic improvements, and a dedicated cardiovascular trial called SURPASS-CVOT is currently underway. Most researchers expect tirzepatide to show comparable or potentially greater cardiovascular benefits, but definitive results aren't yet available.

Do I need existing heart disease to benefit from GLP-1 medications?

The SELECT trial specifically studied people with existing cardiovascular disease, but that doesn't mean others won't benefit. GLP-1 medications improve multiple cardiovascular risk factors—blood pressure, inflammation, weight, lipids—in people without diagnosed heart disease too. Ongoing trials are studying whether these medications prevent first cardiovascular events in lower-risk populations.

How long do you need to take semaglutide to see cardiovascular benefits?

In the SELECT trial, cardiovascular benefits began appearing within the first year and continued throughout the study period. However, this is likely a medication that requires ongoing use. Cardiovascular protection appears to depend on continued treatment, similar to how blood pressure or cholesterol medications work. Always discuss treatment duration with your healthcare provider based on your individual situation.

Disclaimer: Reviewed by the Ozari Clinical Content Team (OCCT) — health writers and wellness professionals specializing in GLP-1 therapy and metabolic health. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, prescribed by licensed providers and shipped to your door. Learn more at ozarihealth.com.